



MEDICAL TIPS

OLMEBLU-AM TABLETS

Issue V, No. 20, 2022

A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study

Jo SH et al. *J Clin Med* 2022; 11(2): 350.

- A study was conducted to evaluate the efficacy and safety of olmesartan/amlodipine single pill plus rosuvastatin combination for the treatment of patients with concomitant hypertension and dyslipidemia.
- Patients were either administered olmesartan/amlodipine single pill plus rosuvastatin or olmesartan plus rosuvastatin or only the olmesartan/amlodipine single pill and sitting SBP and LDL-C from baseline to the end of 8 weeks were evaluated.
- A significant reduction in the sitting SBP (-24.30mmHg) in the olmesartan/amlodipine plus rosuvastatin group was seen as compared to only olmesartan and rosuvastatin.
- Also, a significant reduction in LDL-C (-54.31%) was observed in the olmesartan/amlodipine plus rosuvastatin group as compared to only olmesartan/amlodipine single pill group.

Olmesartan/amlodipine single pill plus rosuvastatin combination for patients with hypertension and dyslipidemia was effective and safe as compared to either olmesartan plus rosuvastatin or olmesartan plus amlodipine.

